Emerging issues in cystic fibrosis newborn screening
Carlo Castellani1, John Massie
1Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. carlo.castellani@ospedaleuniverona.it
Current Opinion in Pulmonary Medicine
|September 4, 2010
Summary
New cystic fibrosis (CF) newborn screening (NBS) strategies are emerging to improve accuracy. Algorithms are adapting to diverse populations and changing sweat test interpretations for better CF detection.
Area of Science:
- Biochemistry
- Genetics
- Neonatal Medicine
Background:
- Cystic Fibrosis (CF) newborn screening (NBS) programs are expanding globally.
- Existing NBS protocols face challenges with population diversity and evolving diagnostic criteria.
- New strategies aim to enhance the sensitivity and specificity of CF detection in newborns.
Purpose of the Study:
- To review emerging issues and new algorithms in cystic fibrosis newborn screening.
- To discuss the adaptation of NBS protocols for diverse populations.
- To highlight changes in the interpretation of diagnostic tests for CF.
Main Methods:
- Review of current cystic fibrosis newborn screening algorithms.
- Analysis of factors affecting immunoreactive trypsinogen values and genetic testing sensitivity.
- Examination of updated sweat test interpretation guidelines for neonates.
Main Results:
- Population mixing impacts NBS results, necessitating algorithm adjustments.
- Non-genetic tiers in algorithms offer an alternative to solely genetic approaches.
- A revised upper limit for normal sweat chloride in neonates is now 29 mmol/l.
- Infants with intermediate sweat chloride values require further clinical evaluation.
- Prenatal diagnosis and carrier screening contribute to reduced CF incidence.
Conclusions:
- No single universal CF NBS protocol fits all regions.
- Algorithms can be tailored to local conditions and population needs.
- Ongoing adaptation of NBS strategies is crucial for effective cystic fibrosis detection.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...